Modality
Fusion Protein
MOA
FXIai
Target
BTK
Pathway
RNA Splicing
OCDEwing Sarcoma
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
~Sep 2021
→ ~Dec 2022
Phase 2
Mar 2023
→ May 2026
Phase 2Current
NCT05788873
277 pts·OCD
2023-03→TBD·Completed
NCT06839699
1,258 pts·Ewing Sarcoma
2025-01→2026-05·Not yet recruiting
1,535 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-05-051mo awayPh2 Data· Ewing Sarcoma
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P2
Complet…
P2
Not yet…
Catalysts
Ph2 Data
2026-05-05 · 1mo away
Ewing Sarcoma
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05788873 | Phase 2 | OCD | Completed | 277 | DOR |
| NCT06839699 | Phase 2 | Ewing Sarcoma | Not yet recr... | 1258 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |